Manila Times Business
Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy
Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy Development programme complements Company’s autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical developmentTogether, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy EDINBURGH, United Kingdom and LONDON, June 17, 20
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
P15-B supplemental budget for Mindanao quake relief, recovery filed
Just now
LEIFRAS Co., Ltd. Issues JPY200 Million SDGs Private Placement Bonds to Establish Robust Financial Foundation and Support Disadvantaged Youth
Just now
Divine Adili's public wake ends as Ateneo prepares send-off mass for Nigerian player
Just now
TOMI Advances Toward NSF Certification to Address Multi-Billion-Dollar Pharmaceutical, Biotech and Cleanroom Decontamination Markets
Just now